Literature DB >> 3619218

Should all pregnant women be screened for hepatitis B?

M L Kumar, N V Dawson, A J McCullough, M Radivoyevitch, K C King, R Hertz, H Kiefer, M Hampson, R Cassidy, A S Tavill.   

Abstract

To assess the sensitivity of historical risk factors for identification for hepatitis B surface antigen (HBsAg)-positive parturients, 4399 pregnant women were consecutively screened for HBsAg. Information regarding risk for hepatitis B infection was obtained from each HBsAg-positive parturient. Twenty-three HBsAg-positive subjects were identified (5.2/1000 deliveries). The HBsAg carrier rate (18/2231, or 8.1/1000 deliveries) was significantly higher in women of black, Asian, or Hispanic origin than in the remaining ethnic groups (non-Hispanic whites plus all others, 5/2168, or 2.3/1000 deliveries) (chi square, 5.95; p = 0.016). Risk factors for identification of HBsAg-positive women were present in 10 of 22 asymptomatic subjects (sensitivity, 45%; 95% confidence interval, 24% to 68%). Much of the information required to assess one of these risk factors, previous infection, involved detailed questioning and is unlikely to be obtained in the context of conventional obstetrical care. Routine maternal HBsAg screening programs may be needed if transmission of hepatitis B from mother to infant is to be prevented.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3619218     DOI: 10.7326/0003-4819-107-2-273

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  11 in total

1.  Screening for hepatitis B during pregnancy. Awareness of current recommendations among Washington hospitals.

Authors:  T R Eng; M L Borges; V K Harlin; J M Kobayashi
Journal:  West J Med       Date:  1991-12

2.  Access to prenatal HIV testing.

Authors:  R S Remis; D M Patrick
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

3.  Screening in pregnancy.

Authors:  A Biringer
Journal:  Can Fam Physician       Date:  1988-09       Impact factor: 3.275

4.  Risk of cross-infection related to the multiple use of disposable syringes.

Authors:  C A Trépanier; M R Lessard; J G Brochu; P H Denault
Journal:  Can J Anaesth       Date:  1990-03       Impact factor: 5.063

Review 5.  Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.

Authors:  S M Holliday; D Faulds
Journal:  Pharmacoeconomics       Date:  1994-02       Impact factor: 4.981

6.  Targeted HIV screening at a Los Angeles prenatal/family planning health center.

Authors:  L J Fehrs; D Hill; P R Kerndt; T P Rose; C Henneman
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

7.  Success of a program of routine prenatal screening for hepatitis B surface antigen: the first 2 years.

Authors:  N B Okun; R P Larke; J R Waters; M R Joffres
Journal:  CMAJ       Date:  1990-12-15       Impact factor: 8.262

8.  Hepatitis B virus sero-prevalence among pregnant females in Saudi Arabia.

Authors:  Mohammed A Alrowaily; Mostafa A Abolfotouh; Mazen S Ferwanah
Journal:  Saudi J Gastroenterol       Date:  2008-04       Impact factor: 2.485

9.  Prevalence of hepatitis B markers among pregnant Hispanic women in migrant/seasonal work in Oregon.

Authors:  L J Fehrs; L Eisele; R Conrad; L R Foster; D Fleming
Journal:  Am J Public Health       Date:  1988-08       Impact factor: 9.308

10.  Adherence to the screening program for HBV infection in pregnant women delivering in Greece.

Authors:  Vassiliki Papaevangelou; Christos Hadjichristodoulou; Dimitrios Cassimos; Maria Theodoridou
Journal:  BMC Infect Dis       Date:  2006-05-09       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.